FOR HEALTHCAREPROFESSIONALS
†Lactulose was used concomitantly by 91% of patients in both arms of the study1
The above data are not a comparison of NNT among different treatments but are intended to provide an overview of published data on NNT.
See XIFAXAN safety profile
HE = hepatic encephalopathy
‡Patient is not eligible if he/she participates in or seeks reimbursement or submits a claim for reimbursement to any federal or state healthcare program with prescription drug coverage, such as Medicaid, Medicare, Medigap, VA, DOD, TRICARE, or any similar federal or state healthcare program (each a Government Program), or where prohibited by law. Patient must be enrolled in, and must seek reimbursement from or submit a claim for reimbursement to, a commercial insurance plan. Offer excludes full cash-paying patients. Maximum benefits and other restrictions apply. Visit https://xifaxan.copaysavingsprogram.com/ or call 1-866-XIFAXAN for full eligibility criteria, terms and conditions.
XIFAXAN has a demonstrated safety profile1
Look up insurance coverage for your patients
Instant Savings Card available for eligible,‡ commercially insured patients
Get information regarding XIFAXAN
Speak with a XIFAXAN representative
Thank you for visiting the XIFAXAN Professional website. By clicking OK, you will be taken to a website or sites where our Privacy Policy and other rules do not apply. Salix Pharmaceuticals does not possess editorial control over the content of the information on such website(s) and therefore does not warrant their accuracy and completeness. You are solely responsible for interactions with such website(s).
XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.